Bristol Myers Squibb stock: Revenue outlook rises as pipeline advances

Published on 10/31/2026 at 10:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock enters the weekend after a quarterly revenue beat and a higher 2026 sales outlook. Pipeline work remains central.

Pipeline progress meets mixed outlook

Third-quarter revenue rose 7 percent to USD 13.07 billion and exceeded analyst expectations.
Management raised its 2026 revenue outlook but reduced adjusted EPS guidance because of acquisition-related charges.
The company is targeting an early 2027 restart for paused zolacabtagene autoleucel trials after reviewing a manufacturing safety issue.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb reported stronger-than-expected third-quarter results on Thursday, October 29, while lowering its adjusted earnings outlook because of acquisition-related charges. Reuters reported that revenue rose 7 percent year over year to USD 13.1 billion, ahead of the USD 12.75 billion analyst forecast, while adjusted earnings reached USD 1.35 per share.

The company now expects 2026 revenue of USD 49.75 billion to USD 50.25 billion, compared with its previous range of USD 49 billion to USD 50 billion. Adjusted EPS guidance moved down to USD 6.35 to USD 6.55 from USD 6.75 to USD 7.00. Reuters attributed the reduction to a charge, while the company continued to benefit from newer medicines.

Newer medicines support sales growth

Growth products remained the main commercial driver. According to Yahoo Finance, Growth Portfolio revenue increased 12 percent to USD 7.7 billion. Eliquis revenue rose 25 percent to USD 4.69 billion, helping the Legacy Portfolio grow 1 percent despite pressure on older medicines.

The quarterly adjusted gross margin fell to 68.4 percent from 72.9 percent a year earlier. Yahoo Finance said the decline reflected product mix changes and a one-time charge linked to the termination of a contract. For investors, the quarter therefore combined stronger demand with a less favorable cost and charge profile.

Clinical milestones shape the next phase

Reuters reported that Bristol Myers is working with the FDA to resume enrollment in zolacabtagene autoleucel trials in early 2027. The company paused the studies in September to review safety data after a patient death and concluded that a reagent used in manufacturing was the root cause of the safety issue. Management said it had adjusted the process and was working with regulators.

Reuters also identified Cobenfy's potential expansion into Alzheimer's disease treatment and the development of milvexian as important future catalysts. Data from trials involving both programs are expected next year.

Bristol Myers Squibb stock traded at EUR 56.12 on Lang & Schwarz at 10:09 CET on Saturday, October 31, 2026. Investors can follow the real-time quote of Bristol Myers Squibb stock.

The S&P 500 provides the broader U.S. market backdrop for the company.

See current S&P 500 market coverage and more news and analyses on Bristol Myers Squibb stock.